175 related articles for article (PubMed ID: 29189513)
1. Successful Nonmyeloablative Allogeneic Stem Cell Transplant in a Child With Emberger Syndrome and GATA2 Mutation.
Rastogi N; Abraham RS; Chadha R; Thakkar D; Kohli S; Nivargi S; Prakash Yadav S
J Pediatr Hematol Oncol; 2018 Aug; 40(6):e383-e388. PubMed ID: 29189513
[TBL] [Abstract][Full Text] [Related]
2. Successful Myeloablative Matched Unrelated Donor Hematopoietic Stem Cell Transplantation in a Young Girl With GATA2 Deficiency and Emberger Syndrome.
Ramzan M; Lowry J; Courtney S; Krueger J; Schechter Finkelstein T; Ali M
J Pediatr Hematol Oncol; 2017 Apr; 39(3):230-232. PubMed ID: 28234738
[TBL] [Abstract][Full Text] [Related]
3. Nonmyeloablative allogeneic hematopoietic stem cell transplantation for GATA2 deficiency.
Grossman J; Cuellar-Rodriguez J; Gea-Banacloche J; Zerbe C; Calvo K; Hughes T; Hakim F; Cole K; Parta M; Freeman A; Holland SM; Hickstein DD
Biol Blood Marrow Transplant; 2014 Dec; 20(12):1940-8. PubMed ID: 25111582
[TBL] [Abstract][Full Text] [Related]
4. [Efficacy of Nonmyeloablative Allogeneic Hematopoietic Stem Cells for 14 Case of Severe Acquired Aplastic Anemia].
Wang SF; Huang YJ; Yu CL; Sun QY; Qiao JH; Hu KX; Zuo HL; Dong Z; Liu ZQ; Wang Y; Huang XM; Ai HS; Guo M
Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2015 Aug; 23(4):1097-102. PubMed ID: 26314453
[TBL] [Abstract][Full Text] [Related]
5. Unmanipulated HLA 2-3 antigen-mismatched (haploidentical) stem cell transplantation using nonmyeloablative conditioning.
Ogawa H; Ikegame K; Yoshihara S; Kawakami M; Fujioka T; Masuda T; Taniguchi Y; Hasei H; Kaida K; Inoue T; Kim EH; Kawase I
Biol Blood Marrow Transplant; 2006 Oct; 12(10):1073-84. PubMed ID: 17084371
[TBL] [Abstract][Full Text] [Related]
6. Unrelated donor hematopoietic stem cell transplantation for patients with hematologic malignancies using a nonmyeloablative conditioning regimen of fludarabine, low-dose total body irradiation, and rabbit antithymocyte globulin.
Rowley SD; Goldberg SL; Pecora AL; Hsu JS; Brecher BA; Butrin L; Kobbe K; McKiernan P; Preti R
Biol Blood Marrow Transplant; 2004 Nov; 10(11):784-93. PubMed ID: 15505609
[TBL] [Abstract][Full Text] [Related]
7. Successful outcome after nonmyeloablative allogeneic hematopoietic stem cell transplantation in patients with renal dysfunction.
Kersting S; Verdonck LF
Biol Blood Marrow Transplant; 2008 Nov; 14(11):1312-6. PubMed ID: 18940687
[TBL] [Abstract][Full Text] [Related]
8. Tacrolimus and mycofenolate mofetil as GvHD prophylaxis following nonmyeloablative conditioning and unrelated hematopoietic SCT for adult patients with advanced hematologic diseases.
Zohren F; Schroeder T; Czibere A; Fenk R; Bruns I; Kondakci M; Saure C; Haas R; Kobbe G
Bone Marrow Transplant; 2011 May; 46(5):747-55. PubMed ID: 20661230
[TBL] [Abstract][Full Text] [Related]
9. A well-tolerated regimen of 800 cGy TBI-fludarabine-busulfan-ATG for reliable engraftment after unmanipulated haploidentical peripheral blood stem cell transplantation in adult patients with acute myeloid leukemia.
Yahng SA; Kim JH; Jeon YW; Yoon JH; Shin SH; Lee SE; Cho BS; Eom KS; Kim YJ; Lee S; Min CK; Cho SG; Kim DW; Lee JW; Min WS; Park CW; Kim HJ
Biol Blood Marrow Transplant; 2015 Jan; 21(1):119-29. PubMed ID: 25300871
[TBL] [Abstract][Full Text] [Related]
10. Reduced-intensity conditioning using fludarabine and antithymocyte globulin alone allows stable engraftment in a patient with dyskeratosis congenita.
Vuong LG; Hemmati PG; Neuburger S; Terwey TH; Vulliamy T; Dokal I; le Coutre P; Dörken B; Arnold R
Acta Haematol; 2010; 124(4):200-3. PubMed ID: 21042011
[TBL] [Abstract][Full Text] [Related]
11. Allogeneic hematopoietic cell transplantation for metastatic renal cell carcinoma after nonmyeloablative conditioning: toxicity, clinical response, and immunological response to minor histocompatibility antigens.
Tykodi SS; Warren EH; Thompson JA; Riddell SR; Childs RW; Otterud BE; Leppert MF; Storb R; Sandmaier BM
Clin Cancer Res; 2004 Dec; 10(23):7799-811. PubMed ID: 15585611
[TBL] [Abstract][Full Text] [Related]
12. Case report: Successful allogeneic stem cell transplantation in a child with novel GATA2 defect associated B-cell acute lymphoblastic leukemia.
Heropolitańska-Pliszka E; Piątosa B; Szmydki-Baran A; Kuczborska K; Miarka-Walczyk K; Pastorczak A; Młynarski W; Sędek Ł; Szczepański T; Ussowicz M
Front Immunol; 2022; 13():928529. PubMed ID: 35983050
[TBL] [Abstract][Full Text] [Related]
13. A fludarabine-based dose-reduced conditioning regimen followed by allogeneic stem cell transplantation from related or unrelated donors in patients with myelodysplastic syndrome.
Kröger N; Schetelig J; Zabelina T; Krüger W; Renges H; Stute N; Schrum J; Kabisch H; Siegert W; Zander AR
Bone Marrow Transplant; 2001 Oct; 28(7):643-7. PubMed ID: 11704786
[TBL] [Abstract][Full Text] [Related]
14. Allogeneic hematopoietic cell transplantation in patients with GATA2 deficiency-a case report and comprehensive review of the literature.
Simonis A; Fux M; Nair G; Mueller NJ; Haralambieva E; Pabst T; Pachlopnik Schmid J; Schmidt A; Schanz U; Manz MG; Müller AMS
Ann Hematol; 2018 Oct; 97(10):1961-1973. PubMed ID: 29947977
[TBL] [Abstract][Full Text] [Related]
15. Total skin electron beam and non-myeloablative allogeneic hematopoietic stem-cell transplantation in advanced mycosis fungoides and Sezary syndrome.
Duvic M; Donato M; Dabaja B; Richmond H; Singh L; Wei W; Acholonu S; Khouri I; Champlin R; Hosing C
J Clin Oncol; 2010 May; 28(14):2365-72. PubMed ID: 20351328
[TBL] [Abstract][Full Text] [Related]
16. MonoMAC Syndrome Caused by a Novel GATA2 Mutation Successfully Treated by Allogeneic Hematopoietic Stem Cell Transplantation.
Moraes-Fontes MF; Caramalho Í; Hsu AP; Holland SM; Abecasis M
J Clin Immunol; 2019 Jan; 39(1):4-6. PubMed ID: 30478525
[No Abstract] [Full Text] [Related]
17. [Treatment of Gaucher disease with allogeneic hematopoietic stem cell transplantation: report of three cases and review of literatures].
Tang X; Luan Z; Wu N; Zhang B; Jing Y; Du H; Lu W; Xu S
Zhonghua Er Ke Za Zhi; 2015 Nov; 53(11):810-6. PubMed ID: 26758318
[TBL] [Abstract][Full Text] [Related]
18. Impact of postgrafting immunosuppressive regimens on nonrelapse mortality and survival after nonmyeloablative allogeneic hematopoietic stem cell transplant using the fludarabine and low-dose total-body irradiation 200-cGy.
Koh LP; Chen CS; Tai BC; Hwang WY; Tan LK; Ng HY; Linn YC; Koh MB; Goh YT; Tan B; Lim S; Lee YM; Tan KW; Liu TC; Ng HJ; Loh YS; Mow BM; Tan DC; Tan PH
Biol Blood Marrow Transplant; 2007 Jul; 13(7):790-805. PubMed ID: 17580257
[TBL] [Abstract][Full Text] [Related]
19. Nonmyeloablative allogeneic hematopoietic stem cell transplantation as immunotherapy for pancreatic cancer.
Abe Y; Ito T; Baba E; Nagafuji K; Kawabe K; Choi I; Arita Y; Miyamoto T; Teshima T; Nakano S; Harada M
Pancreas; 2009 Oct; 38(7):815-9. PubMed ID: 19696692
[TBL] [Abstract][Full Text] [Related]
20. Graft-versus-host disease prophylaxis with tacrolimus and mycophenolate mofetil in HLA-matched nonmyeloablative transplant recipients is associated with very low incidence of GVHD and nonrelapse mortality.
Sabry W; Le Blanc R; Labbé AC; Sauvageau G; Couban S; Kiss T; Busque L; Cohen S; Lachance S; Roy DC; Roy J
Biol Blood Marrow Transplant; 2009 Aug; 15(8):919-29. PubMed ID: 19589481
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
